Protagonist Therapeutics Inc [PTGX] stock is trading at $84.75, down -0.56%. An important factor to consider is whether the stock is rising or falling in short-term value. The PTGX shares have gain 5.67% over the last week, with a monthly amount drifted -10.59%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $72. Previously, Leerink Partners started tracking the stock with Outperform rating on September 12, 2025, and set its price target to $73. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $72 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $47 on December 06, 2024. BMO Capital Markets initiated its recommendation with a Outperform and recommended $62 as its price target on December 06, 2024. Wedbush started tracking with a Outperform rating for this stock on November 05, 2024, and assigned it a price target of $58. In a note dated September 24, 2024, TD Cowen initiated an Buy rating and provided a target price of $65 on this stock.
Protagonist Therapeutics Inc [PTGX] stock has fluctuated between $33.70 and $96.54 over the past year. Currently, Wall Street analysts expect the stock to reach $110 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $84.75 at the most recent close of the market. An investor can expect a potential return of 29.79% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 209.22M for the trailing twelve months, which represents a growth of 0.79%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.07 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Protagonist Therapeutics Inc’s Current Ratio is 13.05. On the other hand, the Quick Ratio is 13.05, and the Cash Ratio is 2.53. Considering the valuation of this stock, the price to sales ratio is 25.32, the price to book ratio is 8.20 and price to earnings (TTM) ratio is 133.80.
Transactions by insiders
Recent insider trading involved MOLINA ARTURO MD, Chief Medical Officer, that happened on Nov 17 ’25 when 2712.0 shares were sold. Director, Waddill William D. completed a deal on Oct 10 ’25 to sell 12000.0 shares. Meanwhile, Director WILLIAM WADDILL bought 12000.0 shares on Oct 10 ’25.
